AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress

–Results will be presented from the Phase 3 M15-736 trial, a randomized, double-blind, double-dummy, active-controlled study, evaluating the continuous subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) in people with advanced Parkinson’s disease
–Data will also be presented on real-world efficacy of BOTOX® (onabotulinumtoxinA) for the treatment of spasticity and BOTOX® for the treatment of cervical dystonia
–Research highlights AbbVie’s continued commitment to advancing the management of movement disorders

AbbVie( NYSE ABBV) moment blazoned that data from its robust neuroscience portfolio will be presented at the 2022 International Parkinson and Movement Disorder Society’s( MDS) International Congress, taking place in Madrid, Spain, from September 15- 18. A aggregate of 13 objectifications will be presented across multiple complaint countries, including Parkinson’s complaint, spasticity and cervical dystonia.

” At AbbVie, we understand the realities and challenges that people living with movement diseases face and are grim in our pursuit to address the unmet requirements,” said Mudra Kapoor,M.D., vice chairman, neuroscience, global medical affairs, AbbVie.” Our exploration presented at this time’s MDS International Congress reinforces our moxie in neuroscience and builds upon our charge to advance treatment for people living with these enervating conditions.”

At MDS, experimenters will present results from M15- 736, a randomized, double-eyeless, double- dummy, active- controlled Phase 3 study, assessing the nonstop subcutaneous infusion of ABBV- 951( foslevodopa/ foscarbidopa) in people with advanced Parkinson’s complaint, as well as real- world data from the ASPIRE study, assessing BOTOX ® for the treatment of spasticity. The data will be presented during the guided bill tenures.

AbbVie abstracts presented at the 2022 MDS International Congress are outlined below. 

Key AbbVie Abstracts at 2022 MDS International Congress
Abstract TitleAbstract Details
Advanced Parkinson’s Disease
Subcutaneous Foslevodopa/Foscarbidopa in Patients with Advanced Parkinson’s Disease: Results from a Randomized,
Double-Blind, Double-Dummy Phase 3 Trial
Friday, September 1613:00-15:00 CESTGuided Poster Tour
Impact of Foslevodopa/Foscarbidopa on Key Clinical and Patient-Reported Outcomes in Patients with aPD: Responder
Analysis of Two Phase 3 Clinical Trials
Friday, September 16
14:00-14:30 CEST
Concomitant Medication Use and Levodopa Equivalent Daily Dose Requirements After Foslevodopa/foscarbidopa InitiationFriday, September 16
13:00-15:00 CESTGuided Poster Tour
Rapid Onset of Good ON Time and Improvement in Motor-State Stability in aPD Patients After Treatment with Continuous
Subcutaneous Foslevodopa/Foscarbidopa
Friday, September 16
13:00-15:00 CESTGuided Poster Tour
Patient and Caregiver Satisfaction of Video-Assisted Telenursing in Patients Treated with Levodopa/Carbidopa Intestinal
Gel (LCIG)
Thursday, September 15
14:00-14:30 CEST
Clinical Outcomes and Disease Burden of Advanced Parkinson’s Disease Patients Treated with Oral Medication Vs.
Device-Aided Therapies: Preliminary Results from the University of Florida Registry Analysis
Saturday, September 17
13:00-13:30 CEST
Reported Clinical and Quality-of-Life Outcomes with 24-Hour Levodopa-Compared with 16-Hour AdministrationSaturday, September 17
13:00-13:30 CEST
 Spasticity
Pain and Disability Outcomes in Hemiparetic Patients Naive to Botulinum Toxins with Upper and Lower Limb Spasticity Treated
with OnabotulinumtoxinA: Insights from the ASPIRE Study
Friday, September 16
13:00-13:30 CEST
Treating Upper Limb Spasticity with OnabotulinumtoxinA: Subgroup Analysis of US Practice Patterns from the ASPIRE StudyFriday, September 16
14:00-14:30 CESTGuided Poster Tour
Real-World Clinical Utilization Differences of OnabotulinumtoxinA and AbobotulinumtoxinA in Upper Limb SpasticityFriday, September 16
14:30-15:00 CEST
Pain and Disability Outcomes in Hemiparetic Patients with Post-Stroke Spasticity: Exploratory Analysis of the ASPIRE StudyFriday, September 16
14:30-15:00 CEST
Cervical Dystonia
Characteristics and Treatment Response to OnabotulinumtoxinA of Patients from CD-PROBE with Retrocollis Subtype of
Cervical Dystonia
Friday, September 16
13:00-13:30 CEST
Characteristics and Treatment Response to OnabotulinumtoxinA of Patients from CD-PROBE with Anterocollis Subtype of
Cervical Dystonia
Friday, September 16
13:00-13:30 CEST

The 2022 MDS International Congress is a hybrid meeting taking place in-person and virtually. The virtual platform features on-demand recordings of scientific sessions, a poster hall, and an exhibition hall, all of which will become available after the in-person congress concludes. The full 2022 MDS International Congress program can be found here.

About BOTOX ®
BOTOX ® was first approved by the FDA in 1989 for two rare eye muscle diseases – blepharospasm and hypermetropia in grown-ups. moment, BOTOX ® is FDA- approved for 12 remedial suggestions, including habitual migraine, hyperactive bladder, leakage of urine( incontinence) due to hyperactive bladder caused by a neurologic condition in grown-ups and in pediatric cases five times of age and aged, cervical dystonia, adult and pediatric spasticity, and severe underarm sweating( axillary hyperhidrosis). Botulinum poison units aren’t exchangeable from one product to another; boluses recommended in Allergan Units are different from other botulinum poison medications.
About ABBV- 951
ABBV- 951 is an investigational subcutaneous delivery of levodopa/ carbidopa being estimated for the treatment of advanced levodopa- responsive Parkinson’s complaint with severe motor oscillations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products haven’t given satisfactory results. ABBV- 951 is an investigational remedy and it isn’t approved for use.

About AbbVie in Neuroscience
At AbbVie, our commitment to save the personhood of those living with neurological and psychiatric diseases is unwavering. Every challenge in this uncharted home makes us further determined and drives us harder to discover and deliver results for cases, care mates and clinicians. AbbVie’s Neuroscience portfolio consists of approved curatives and a robust channel in neurological and psychiatric diseases, including Alzheimer’s complaint, bipolar I complaint, major depressive complaint, migraine, Parkinson’s complaint, spinal cord injuries,post-stroke spasticity, schizophrenia, stroke and others.

We’ve a strong investment in neuroscience exploration, with our Foundational Neuroscience Center in Cambridge, Massachusetts, and our Neuroscience Discovery point in Ludwigshafen, Germany, where our exploration and adaptability in these grueling remedial areas is yielding a deeper understanding of the pathophysiology of neurological and psychiatric diseases, and relating targets for implicit complaint- modifying rectifiers aimed at making a difference in people’s lives.

About AbbVie
AbbVie’s charge is to discover and deliver innovative drugs that break serious health issues moment and address the medical challenges of hereafter. We strive to have a remarkable impact on people’s lives across several crucial remedial areas immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Source link:https://news.abbvie.com/

Leave a Reply

Your email address will not be published.